Long-term follow-up for patients with alcoholic liver cirrhosis treated with Cellgram-LC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the long-term safety of Cellgram-LC in patients with alcoholic liver cirrhosis who previously participated in the PMC-P-07 clinical trial. Participants will be monitored for 60 months following a single dose of the treatment to assess any potential adverse effects or complications. The study aims to gather comprehensive data on the safety profile of Cellgram-LC over an extended period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants who received Cellgram-LC in the PMC-P-07 clinical trial.
2. Participants who voluntarily provide written informed consent to participate in this study.

Exclusion Criteria:

\- None.

Where it's running

• Korea University Ansan Hospital
  Ansan, South Korea Recruiting
• Soonchunhyang University Hospital
  Bucheon-si, South Korea Recruiting
• Hallym Univ. Medical Center
  Chuncheon, South Korea Recruiting
• Gangneung Asan Hospital
  Gangneung-si, South Korea Recruiting
• Eunpyeong St. Mary's Hospital
  Seoul, South Korea Recruiting
• Gangnam Severance Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Moonyoung Kim — Wonju Severance Christian Hospital
• Study coordinator: Yujeong Kim
• Email: yjkim@pharmicell.com
• Phone: 82-2-3496-0137

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TAK-242 and G-CSF in ACLF: a new treatment approach for adults with acute-on-chronic liver failure

  This trial tests whether adding TAK-242, with or without G-CSF, to standard ACLF care helps patients with severe alcoholic hepatitis and ACLF.

  Recruiting Phase 2 Yaqrit Ltd · London, Greater London · NCT06890039

• Assessing heart function in patients with liver cirrhosis undergoing TIPSS placement

  This study is testing how heart function changes in patients with severe liver cirrhosis who are getting a specific procedure called TIPSS to see if it affects their heart health over the next year.

  Recruiting Jena University Hospital · Jena, Thuringia · NCT06814990

• Optimizing recovery in patients with alcohol-related liver cirrhosis

  This study is testing if motivational interviews along with regular care can help people with alcohol-related liver cirrhosis improve their liver function and slow down the disease.

  Recruiting Copenhagen University Hospital, Hvidovre · Hvidovre, Capital Region · NCT06866496

• Evaluating Cellgram-LC for Alcoholic Cirrhosis Treatment

  This study is testing whether a new treatment using stem cells can help people with alcoholic cirrhosis feel better and improve their liver health.

  Recruiting at 12 sites Phase 3 Pharmicell Co., Ltd. · Ansan and 14 other locations · NCT04689152

• Evaluating SAMe for improving liver function in patients with alcoholic cirrhosis

  This study is testing if a supplement called SAMe can help improve liver function in people with alcoholic cirrhosis.

  Recruiting at 2 sites Phase 2 Indiana University · Los Angeles, California and 1 other locations · NCT04250259

• Understanding genetic factors in alcoholic liver disease

  This study looks at how common alcoholic hepatitis is in people with jaundice and tries to understand the role of genetics in the disease while also testing new ways to diagnose it.

  Recruiting at 9 sites University Hospital, Lille · Angers and 8 other locations · NCT04106518

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.